India CDMOs Seek To Counter China With New Industry Body, See Europe As Ally

US Tariff Plan Throws Spanner In The Works

07 Mar 2025

Indian CDMOs could consider collaborating with allies in Europe amid a focused effort via a new industry body to counter existing challenges like China’s manufacturing, regulatory and policy advantages and a shortage of funding and talent in the country even as talk of US tariffs throws a new spoke in the wheel

CRDMO Panel at BioAsia 2025 — L to R: Vikash Agarwalla, MD & Partner, BCG; Peter Bains, CEO Designate, Syngene; Manni Kantipudi, CEO, Aragen Lifesciences; Nandini Piramal, Chairperson, Piramal Pharma; Guilano Perfetti, MD & CEO, Jubilant Biosys; Krishna Kanumuri, MD & CEO, Sai Lifesciences; Akhil Ravi, CEO, Aurigene Pharma; Srivari Chandrashekhar, former director BCT (Source -Citeline)

The global pharmaceutical industry’s dependence on China for raw materials like starting materials, intermediates and active pharmaceutical ingredients (APIs) is a well-known supply chain threat.

As US President Donald Trump addresses this in his own way by increasing tariffs on China and urging US companies to opt for onshoring of manufacturing, successfully so in some cases like that of Eli Lilly, Indian contract research,

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Lupin CEO On Trump’s Most Favored Nation Policy, Tariffs, Firm’s Five-Year Plan

16 May 2025

• By Vibha Ravi

Lupin CEO Vinita Gupta speaks on Trump’s most favored nation policy, the Inflation Reduction Act’s “pill penalty” and other developments in the US, a major market for the company. The company also outlines a five-year plan focused on complex generics and technology platforms.

UK-India FTA Could Offer ‘Significant Benefits’ For Generics, Biosimilars

15 May 2025

• By Dave Wallace

A free trade agreement between the UK and India could offer “significant benefits for the generic and biosimilar sectors,” Medicines UK believes. The off-patent industry association has also suggested further avenues for collaboration between the two governments.

Cipla Leadership’s Early Take On Trump’s Pricing EO And Pipeline Progress

15 May 2025

• By Anju Ghangurde

Cipla's CEO underlines that US generic prices are already “very significantly comparable” with the rest of the world and expects President Donald Trump's executive order on drug pricing to primarily impact branded pharmaceuticals. The company also shared updates on its US pipeline.

Dr Reddy’s Gears For Tariffs Scenario To Ensure No US Supply Disruption

12 May 2025

• By Anju Ghangurde

Dr. Reddy's Laboratories preps for potential US tariffs, focusing on sustaining product supply and collaborating with customers on inventories. A recent US plant sale, the firm stressed, was unrelated to tariffs and underlines its openness to ‘make in the US’, where it launched 18 products in fiscal 2025.

Roche Reveals Another US Manufacturing Site As Tariff Pressures Seem To Ease

12 May 2025

• By Mandy Jackson

Roche/Genentech unveiled plans for a $700m-plus manufacturing facility for weight loss drugs in North Carolina as President Trump signaled such investments could mean no tariffs for pharma.